Nurix (NRIX) CSO Gwenn Hansen Sells Shares After Exercising Options

What Happened Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), exercised 1,452 stock option shares and immediately sold those shares in the open market on 2026-09-01. The options were exercised at $1.86 per share (total cash cost $2,701) and the shares were sold at $25.47 per share for total gross proceeds of $36,982. The filing also reports a related derivative conversion entry at $0 consideration for the same 1,452 shares.

Key Details

• Transaction date: 2026-09-01
• Exercise (M): 1,452 shares acquired at $1.86 each — $2,701 total
• Sale (S): 1,452 shares sold at $25.47 each — $36,982 total
• Related derivative conversion (M) reported for 1,452 shares at $0.00 consideration
• Filing notes: transaction was effected pursuant to a Rule 10b5-1 trading plan (footnote F1)
• Vesting context: the option vested monthly (1/48) from June 10, 2019 and was fully vested May 10, 2023 (footnote F2)
• Shares owned after transaction: not specified in this filing
• Filing timeliness: filed on 2026-09-01 for a 2026-09-01 transaction (no late filing indicated)

Context This sequence (exercise then immediate sale) is commonly a cashless outcome where an insider converts vested options into shares and sells them, often under a prearranged 10b5-1 plan. Sales do not necessarily signal negative views; 10b5-1 plans are used to schedule routine disposals. The filing is factual and does not state any insider motivation.